Hong, J., Kwon, G. Y., Kang, M., Seo, S. I., & Park, S. H. (2024). Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study. Korean Urological Oncology Society.
Chicago-referens (17:e uppl.)Hong, Joohyun, Ghee Young Kwon, Minyong Kang, Seong Il Seo, och Se Hoon Park. Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study. Korean Urological Oncology Society, 2024.
MLA-referens (9:e uppl.)Hong, Joohyun, et al. Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study. Korean Urological Oncology Society, 2024.